Announced Thu, 13 Aug · 12:44 IST
Wanbury gets EDQM nod for Rivaroxaban API, USFDA DMF clearances
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.0%1-day move
₹262.35
prior close
₹249.85
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+0.6+0.8+1.3-2.0-4.2-2.4+2.2+1.6—————
Up moveDown movePending
AI summary
Wanbury Limited received EDQM approval for new product Rivaroxaban API, enabling it to meet customer demand in EU and CEP-accepting countries. The company also secured USFDA DMF clearance for Paroxetine HCl and Metformin HCl, with ANDA review underway for multiple customers.
Likely market impact
Opens access to EU and US regulated markets, supporting revenue growth from new and existing API products.